Livagen: Liver & Hepatic Function Bioregulator Research
Tetrapeptide bioregulator for liver tissue and metabolic health
Source: https://indexalabs.com/blog/livagen-bioregulator-liver-hepatic-research Abstract: Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator targeting hepatocytes and liver tissue. Research examines its potential for liver function support, hepatoprotection, and metabolic optimization.
1. Overview & Background
1.1 What is Livagen? Livagen is a tetrapeptide (Lys-Glu-Asp-Ala) bioregulator designed to support liver tissue function and regeneration.
1.2 Target Tissue Primary: Hepatocytes (liver cells) Secondary: Kupffer cells, stellate cells, and hepatic microenvironment
1.3 Liver Function The liver performs over 500 functions including detoxification, protein synthesis, and metabolic regulation. Age and lifestyle factors can impair hepatic function.
2. Mechanisms of Action
2.1 Hepatocyte Support Research suggests Livagen may support hepatocyte viability, proliferation, and functional capacity.
2.2 Detoxification Pathways Studies indicate potential upregulation of phase I and phase II detoxification enzymes.
2.3 Protein Synthesis May influence hepatic protein synthesis including albumin and clotting factors.
2.4 Metabolic Function Potential effects on glucose and lipid metabolism through hepatic enzyme modulation.
3. Research Evidence
3.1 Hepatoprotection Animal studies show protective effects against toxin-induced liver damage.
3.2 Liver Enzymes Research demonstrates normalization of elevated liver enzymes in various models.
3.3 Regeneration Studies Some evidence for enhanced liver regeneration following partial hepatectomy.
3.4 Metabolic Parameters Studies show improvements in lipid profiles and glucose handling.
4. Research Protocols
4.1 Vial Size Available in 20mg vials for research applications.
4.2 Liver Function Monitoring Research requires appropriate liver enzyme and function panels.
4.3 Combination Approaches Often studied with hepatoprotective compounds and lifestyle modifications.
4.4 Timing Considerations Some protocols consider hepatic circadian rhythms in dosing schedules.